Evogene (NASDAQ:EVGN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Evogene to post earnings of ($0.73) per share and revenue of $3.63 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Evogene Trading Down 0.7 %
Shares of EVGN opened at $1.41 on Thursday. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40. The firm’s 50-day moving average price is $1.58 and its 200-day moving average price is $2.18. The firm has a market capitalization of $7.56 million, a price-to-earnings ratio of -0.32 and a beta of 1.29.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Evogene in a research note on Saturday, February 22nd. They issued a “sell” rating on the stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Buffett’s on the Sidelines – Should You Follow?
- How to Short Nasdaq: An Easy-to-Follow Guide
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Stock Sentiment Analysis: How it Works
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
